NASDAQ:OTLK Outlook Therapeutics (OTLK) Stock Price, News & Analysis $8.56 +0.22 (+2.64%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$8.34▼$8.7050-Day Range$6.79▼$9.2252-Week Range$4.00▼$34.80Volume303,594 shsAverage Volume217,204 shsMarket Capitalization$200.39 millionP/E RatioN/ADividend YieldN/APrice Target$46.43 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Outlook Therapeutics alerts: Email Address Outlook Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.88 Rating ScoreUpside/Downside442.3% Upside$46.43 Price TargetShort InterestBearish14.28% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.44Based on 9 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($4.08) to ($2.44) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.99 out of 5 starsMedical Sector806th out of 936 stocksBiological Products, Except Diagnostic Industry138th out of 154 stocks 3.4 Analyst's Opinion Consensus RatingOutlook Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageOutlook Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Outlook Therapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted14.28% of the float of Outlook Therapeutics has been sold short.Short Interest Ratio / Days to CoverOutlook Therapeutics has a short interest ratio ("days to cover") of 9.Change versus previous monthShort interest in Outlook Therapeutics has recently increased by 9.74%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldOutlook Therapeutics does not currently pay a dividend.Dividend GrowthOutlook Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for OTLK. Previous Next 1.9 News and Social Media Coverage News SentimentOutlook Therapeutics has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Outlook Therapeutics this week, compared to 4 articles on an average week.Search InterestOnly 19 people have searched for OTLK on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 7 people have added Outlook Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -72% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Outlook Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.40% of the stock of Outlook Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 11.20% of the stock of Outlook Therapeutics is held by institutions.Read more about Outlook Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Outlook Therapeutics are expected to grow in the coming year, from ($4.08) to ($2.44) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Outlook Therapeutics is -0.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Outlook Therapeutics is -0.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Outlook Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has led to a massive bull run in the year after it happens. That means we're in the "golden window" right now…Check out the new "Crypto Bull Run Millionaire Blueprint" now! About Outlook Therapeutics Stock (NASDAQ:OTLK)Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.Read More OTLK Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart OTLK Stock News HeadlinesJuly 11, 2024 | marketbeat.com3 Beaten Down Pharmaceuticals With Catalysts for Higher PricesTrading volume spikes in beaten-down stocks often signal a bottom for prices investors can bank on. The problem is that beaten-down stocks are usually in that position for a good reason, so it helps if there is a catalyst for higher share prices in addition to the trading volume.July 11, 2024 | marketbeat.com3 Beaten Down Pharmaceuticals With Catalysts for Higher Prices Beaten-down stocks offer value to investors, but not all are worth buying. This is a look at three biopharma at long-term lows with catalysts for higher prices.July 27, 2024 | The Oxford Club (Ad)Man Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new company could become the next to soar like Nvidia.July 26 at 8:25 PM | msn.comESG Outlook: Green Story's Akhil Sivanandan on Helping Brands Unlock Sustainability Data PotentialJuly 26 at 8:25 PM | msn.comESG Outlook: Ladianne Henderson of WoolTribe on Why Sustainability is Everyone's ProblemJuly 24 at 4:38 AM | uk.finance.yahoo.comFrance Telehealth Market Outlook to 2033, with Focus on Teladoc Health Inc, Siemens Healthineers and Philips Healthcare InformaticsJuly 24 at 4:38 AM | finance.yahoo.comGermany Electronic Health Records Market Outlook to 2033, Featuring Cerner Corp, Constellation Software, Concentrix and CompuGroup MedicalJuly 23, 2024 | usnews.comComputer Parts Maker Logitech Lifts Outlook After Upbeat QuarterJuly 27, 2024 | The Oxford Club (Ad)Man Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new company could become the next to soar like Nvidia.July 23, 2024 | finance.yahoo.comFreddie Mac Multifamily’s 2024 Midyear Outlook Forecasts Low Rent Growth Amid High-Supply HeadwindsJuly 22, 2024 | americanbankingnews.comOutlook Therapeutics, Inc. (NASDAQ:OTLK) Receives Average Recommendation of "Moderate Buy" from BrokeragesJuly 8, 2024 | globenewswire.comOutlook Therapeutics® Announces UK MHRA Marketing Authorization of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMDJuly 8, 2024 | globenewswire.comOutlook Therapeutics® Announces UK MHRA Marketing Authorization of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMDJune 11, 2024 | globenewswire.comOutlook Therapeutics® to Present at the Virtual Investor Pitch ConferenceMay 29, 2024 | finance.yahoo.comGlobal Sustainable Aviation Fuel (SAF) Market Outlook 2030 with Neste, World Energy, Gevo, Aemetis, and SkyNRG Dominating the $25 Billion IndustryMay 29, 2024 | markets.businessinsider.comBuy Rating Justified by Outlook Therapeutics’ Advancements and Market ProspectsMay 28, 2024 | msn.comOutlook gets EU approval for Lytenava for wet AMDMay 28, 2024 | globenewswire.comOutlook Therapeutics® Receives European Commission Marketing Authorization for LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMDSee More Headlines Receive OTLK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Outlook Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/15/2024Today7/27/2024Next Earnings (Estimated)8/12/2024Fiscal Year End9/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:OTLK CUSIPN/A CIK1649989 Webwww.outlooktherapeutics.com Phone(609) 619-3990FaxN/AEmployees20Year FoundedN/APrice Target and Rating Average Stock Price Target$46.43 High Stock Price Target$100.00 Low Stock Price Target$20.00 Potential Upside/Downside+442.3%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($11.41) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-58,980,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-167.29% Debt Debt-to-Equity RatioN/A Current Ratio1.07 Quick Ratio1.07 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($1.11) per share Price / Book-7.71Miscellaneous Outstanding Shares23,410,000Free Float22,610,000Market Cap$200.39 million OptionableOptionable Beta0.71 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Ralph H. Thurman (Age 75)Independent Executive Chairman Comp: $207.5kMr. C. Russell Trenary III (Age 66)President, CEO & Director Comp: $610.9kMr. Lawrence A. Kenyon CPA (Age 58)Executive VP, CFO, Treasurer, Company Secretary & Director Mr. Jeffrey Evanson (Age 55)Chief Commercial Officer Comp: $451.17kMs. Alicia TozierSenior Vice President, Marketing & Market AccessMr. Joel PrieveSenior Vice President of Licensing and M&ADr. Surendra Sharma M.D.Senior Vice President of Medical AffairsDr. Jennifer M. Kissner Ph.D.Senior Vice President of Clinical Development & Regulatory AffairsMr. Jedd ComiskeySenior VP - Head of EuropeMore ExecutivesKey CompetitorsCoherus BioSciencesNASDAQ:CHRSChampions OncologyNASDAQ:CSBRProtara TherapeuticsNASDAQ:TARABrainstorm Cell TherapeuticsNASDAQ:BCLIIdera PharmaceuticalsNASDAQ:IDRAView All CompetitorsInsiders & InstitutionsLVW Advisors LLCBought 47,730 shares on 7/16/2024Ownership: 0.204%Rosalind Advisors Inc.Bought 138,225 shares on 7/12/2024Ownership: 1.922%Virtu Financial LLCSold 49,933 shares on 5/20/2024Ownership: 0.140%American International Group Inc.Sold 74,302 shares on 5/14/2024Ownership: 0.030%Vanguard Group Inc.Sold 6,219,100 shares on 5/10/2024Ownership: 2.623%View All Insider TransactionsView All Institutional Transactions OTLK Stock Analysis - Frequently Asked Questions How have OTLK shares performed this year? Outlook Therapeutics' stock was trading at $7.88 at the beginning of 2024. Since then, OTLK stock has increased by 8.6% and is now trading at $8.56. View the best growth stocks for 2024 here. How were Outlook Therapeutics' earnings last quarter? Outlook Therapeutics, Inc. (NASDAQ:OTLK) issued its earnings results on Wednesday, May, 15th. The company reported ($1.55) EPS for the quarter, missing the consensus estimate of ($0.88) by $0.67. When did Outlook Therapeutics' stock split? Outlook Therapeutics shares reverse split on the morning of Thursday, March 14th 2024. The 1-20 reverse split was announced on Thursday, March 14th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, March 14th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. Who are Outlook Therapeutics' major shareholders? Outlook Therapeutics' top institutional investors include Rosalind Advisors Inc. (1.92%) and LVW Advisors LLC (0.20%). Insiders that own company stock include Jeff Evanson, Terry Dagnon, Kurt J Hilzinger, Yezan Munther Haddadin, C Russell Trenary III and Ghiath M Sukhtian. View institutional ownership trends. How do I buy shares of Outlook Therapeutics? Shares of OTLK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Outlook Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Outlook Therapeutics investors own include Matinas BioPharma (MTNB), KushCo (KSHB), Bionano Genomics (BNGO), SCYNEXIS (SCYX), ADMA Biologics (ADMA) and Zosano Pharma (ZSAN). This page (NASDAQ:OTLK) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | Sponsored4 Steps to Survive the Coming Market CrashCracks threaten us with a widespread collapse unlike anything we've seen in our lifetime. During this prese...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Outlook Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Outlook Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free OTLK Stock Alerts